The efficacy and safety of tianeptine in the treatment of depressive disorder: Results of a controlled double-blind multicentre study vs. amitriptyline

G. Invernizzi, E. Aguglia, A. Bertolino, M. Casacchia, N. Ciani, G. F. Marchesi, M. Nardini, V. Rapisarda

Research output: Contribution to journalArticlepeer-review

Abstract

Three hundred in- and outpatients suffering from depressive disorder, as diagnosed using DSM-III criteria were treated for 6 weeks under double-blind conditions in a multicenter controlled study of tianeptine vs. amitriptyline. Both groups presented steady improvement of depressive syndrome from day 7 up to the end of the treatment, as shown by all evaluation scales: HDRS, SAD, CGI. Furthermore, anxiety linked to the depressive syndrome decreased equally in both groups, as shown by the HARS measurements. In addition to the improvement of mood, the tianeptine-treated patients presented less somatic complaints and side effects when compared to the reference antidepressant. These results confirm previous findings that tianeptine is an effective antidepressant with a lower side effect profile than amitriptyline.

Original languageEnglish
Pages (from-to)85-93
Number of pages9
JournalNeuropsychobiology
Volume30
Issue number2-3
Publication statusPublished - 1994

Keywords

  • Acceptability
  • Amitriptyline
  • Antidepressants
  • Anxiety
  • Depression
  • Efficacy
  • Somatic complaints
  • Tianeptine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Fingerprint Dive into the research topics of 'The efficacy and safety of tianeptine in the treatment of depressive disorder: Results of a controlled double-blind multicentre study vs. amitriptyline'. Together they form a unique fingerprint.

Cite this